**Supplementary File 2: Measures of intervention fidelity in the A2B trial**

| **Site** | **Number of patients included in A2B analysis\*** | **Score for fidelity: correct treatment administered** | **Score for fidelity: RASS -2 or lighter achieved** | **Score for dose: RASS recorded at least once per day** | **Score for reach: proportion of eligible patients randomised‡** | **RAG Total score** | **Categorisation of RAG Total score** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 1 | 0 | 3 | 3 | 0 | 6 | Lowest adherence (6-7) |
| 2 | 1 | 3 | 3 | 3 | 3 | 12 | High adherence (10-12) |
| 3 | 3 | 3 | 3 | 2 | 2 | 10 | High adherence (10-12) |
| 4 | 6 | 3 | 2 | 3 | 1 | 9 | Moderate adherence (8-9) |
| 5 | 6 | 3 | 3 | 3 | 0 | 9 | Moderate adherence (8-9) |
| 6 | 8 | 2 | 1 | 3 | 0 | 6 | Lowest adherence (6-7) |
| 7 | 8 | 2 | 2 | 3 | 0 | 7 | Lowest adherence (6-7) |
| 8 | 8 | 3 | 3 | 3 | 3 | 12 | High adherence (10-12) |
| 9 | 9 | 2 | 3 | 2 | 0 | 7 | Lowest adherence (6-7) |
| 10 | 12 | 3 | 3 | 3 | 3 | 12 | High adherence (10-12) |
| 11 | 14 | 3 | 3 | 3 | 2 | 11 | High adherence (10-12) |
| 12 | 16 | 3 | 3 | 3 | 2 | 11 | High adherence (10-12) |
| 13 | 18 | 2 | 3 | 3 | 0 | 8 | Moderate adherence (8-9) |
| 14 | 19 | 2 | 3 | 3 | 2 | 10 | High adherence (10-12) |
| 15 | 20 | 2 | 3 | 3 | 0 | 8 | Moderate adherence (8-9) |
| 16 | 20 | 2 | 2 | 3 | 1 | 8 | Moderate adherence (8-9) |
| 17 | 21 | 3 | 3 | 3 | 2 | 11 | High adherence (10-12) |
| 18 | 22 | 3 | 2 | 3 | 2 | 10 | High adherence (10-12) |
| 19 | 25 | 3 | 3 | 3 | 2 | 11 | High adherence (10-12) |
| 20 | 29 | 3 | 2 | 3 | 1 | 9 | Moderate adherence (8-9) |
| 21 | 30 | 3 | 2 | 3 | 1 | 9 | Moderate adherence (8-9) |
| 22 | 30 | 2 | 3 | 3 | 0 | 8 | Moderate adherence (8-9) |
| 23 | 30 | 2 | 3 | 3 | 0 | 8 | Moderate adherence (8-9) |
| 24 | 30 | 3 | 2 | 3 | 1 | 9 | Moderate adherence (8-9) |
| 25 | 33 | 3 | 3 | 3 | 0 | 9 | Moderate adherence (8-9) |
| 26 | 33 | 2 | 3 | 3 | 0 | 8 | Moderate adherence (8-9) |
| 27 | 36 | 3 | 3 | 3 | 2 | 11 | High adherence (10-12) |
| 28 | 37 | 3 | 3 | 3 | 0 | 9 | Moderate adherence (8-9) |
| 29 | 38 | 3 | 3 | 3 | 0 | 9 | Moderate adherence (8-9) |
| 30 | 47 | 3 | 3 | 3 | 1 | 10 | High adherence (10-12) |
| 31 | 59 | 2 | 2 | 3 | 3 | 10 | High adherence (10-12) |
| 32 | 63 | 2 | 3 | 3 | 0 | 8 | Moderate adherence (8-9) |
| 33 | 65 | 2 | 3 | 3 | 0 | 8 | Moderate adherence (8-9) |
| 34 | 67 | 3 | 2 | 3 | 1 | 9 | Moderate adherence (8-9) |
| 35 | 77 | 3 | 2 | 3 | 2 | 10 | High adherence (10-12) |
| 36 | 89 | 3 | 2 | 3 | 1 | 9 | Moderate adherence (8-9) |
| 37 | 96 | 3 | 3 | 3 | 0 | 9 | Moderate adherence (8-9) |
| 38 | 146 | 2 | 3 | 3 | 1 | 9 | Moderate adherence (8-9) |
| \*Includes all patients in the analysis population and recorded as being on ventilation for at least part of the follow-up period. | | | | | | |  |
| ‡ All randomised patients included – even those excluded from the A2B analysis population. | | | | | |  |  |